注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
NeuBase Therapeutics Inc是壹家臨床前階段生物制藥公司。該公司正在開發模塊化肽核酸(PNA)反義寡核苷酸(PATrOL)平臺,以治療遺傳疾病。PATrOL支持的抗基因療法旨在通過將合成方法的優勢與反義技術的精確性相結合,改進當前的遺傳醫學策略。其項目包括HD的NT-0100、1型肌強直性營養不良(DM1)的NT-0200和KRAS驅動的癌癥的NT-0300。NT-0100程序是壹個開發中的PATrOL支持的治療程序,以靶向HD信使核糖核酸(mRNA)的突變擴增。NT-0200程序是壹個開發中的PATrOL支持的治療程序,以靶向DM1疾病mRNA中的突變擴增。NT-0300程序是壹個正在開發中的PATrOL支持的治療程序,用以靶向突變KRAS基因。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Robert Zamboni | - | - | Chief of Preclinical Development & Member of Scientific Advisory Board |
Dov A. Goldstein | 55 | 2019 | Independent Chairperson |
Eric I. Richman | 62 | 2019 | Independent Director |
Robert Friedlander | - | - | Chair of Scientific Advisory Board |
George McDonald Church | 69 | 2023 | Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board |
Peter Nielsen | - | 2020 | Member of Gene Editing & Scientific Advisory Board |
Randy Davis | - | 2020 | Member of Scientific Advisory Board |
Eriks Rozners | - | 2020 | Member of Gene Editing & Scientific Advisory Board |
Gerald J. Mcdougall | 56 | 2021 | Independent Director |
Danith H. Ly | - | 2019 | Member of Advisory Board |
Steven F. Dowdy | - | 2019 | Member of Gene Editing & Scientific Advisory Board |
James M. Coull | - | 2023 | Member of Gene Editing Advisory Board |
Jeremy Stark | - | 2023 | Member of Gene Editing Advisory Board |
Dietrich A. Stephan | 54 | 2019 | Founder, President & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核